Cincinnati
|
University of Cincinnati |
Funded |
Generated |
|
|---|---|---|---|
| XIAOTING ZHANG, PHD
The ER/MED1 Axis and Mammary Stem/Progenitor Cells |
[Breast Cancer]
2011 |
$60,000 |
$1,807,125 |
| JINSONG ZHANG, PHD
Role of E Protein Inactivation in Leukemogenesis by AML1-ETO |
[Leukemia]
2008 |
$35,000 |
$1,935,998 |
| NEVILLE TAM, PHD
Dietary Soy and Epigenetic Modulation in Androgen-independent Prostrate Cancer |
[Prostate Cancer]
2008 |
$49,857 |
$375,623 |
| RODNEY PETER DEKOTER, PHD
A Mouse Model of Myeloid Leukemia Caused By a Novel Hypomorphic Mutation of PU.1 |
[Leukemia]
2007 |
$50,000 |
$1,762,130 |
| SHAN LU, PHD
The molecular pathway of Vav3-mediated androgen receptor activation in prostate cancer |
[Prostate Cancer]
2006 |
$50,000 |
$1,325,359 |
| ANA LUISA KADEKARO, PHD
Defining the Regulation of p53 and its Pathway by Autocrine/Paracrine Factors in UVR-irradiated Human Melanocytes |
[Skin Cancer]
2006 |
$49,998 |
$429,788 |
| MARIO MEDVEDOVIC, PHD
Global gene expression profiles for the very early prediction of breast cancer |
[Breast Cancer]
2005 |
$25,000 |
|
| CRAIG R TOMLINSON, PHD
Global gene expression profiles for the very early prediction of breast cancer |
[Breast Cancer]
2005 |
$25,000 |
|
| YOLANDA SANCHEZ, PHD
The Role of Sfp1 in the Response to DNA Damage |
[Gene Mutation]
2004 |
$50,000 |
|
| YING XIA, PHD
Role of MEKK1 in Anticancer Treatment |
[Chemotherapy]
2002 |
$50,000 |
$5,067,800 |
| ZALFA A ABDEL-MALEK, PHD
Oxygen Radicals Mediate the Mutagenic Effects of UVA on Melanocytes |
[Skin Cancer]
2001 |
$16,716 |
$4,128,744 |
| SHIUH WEN LUOH, MD
HER-2/NEU Amplification In Human Breast Cancer |
[Breast Cancer]
2001 |
$50,000 |
|
| ANDREW M LOWY, MD
Tcf/beta catenin transactivation in gastric cancer |
[Stomach Cancer]
2001 |
$49,690 |
$2,787,581 |
| JEFFREY J SUSSMAN, MD
Immune Response Modulation Improves Cancer Immunotherapy |
[Skin Cancer]
1999 |
$24,335 |
$112,020 |
| YOLANDA SANCHEZ, PHD
Identification of novel components of the DNA damage checkpoint pathways |
[Gene Mutation]
1999 |
$50,000 |
$7,794,074 |
| DAVID ASKEW, PHD
Function of the His-1 Gene in Leukemogenesis |
[Leukemia]
1999 |
$24,000 |
|
| ARTHUR BUCKLEY, PHD
Novel Tumor Growth, Differentiation, and Apoptosis Genes |
[Genetic Research]
1999 |
$48,000 |
|
| ERIK KNUDSEN, PHD
Retinoblastoma Tumor Suppressor: Role in Checkpoint Control |
[Gene Mutation]
1999 |
$48,000 |
$1,430,446 |
| GLENN TALASKA, PHD
Benzidine and B-naphitylamine DNA Adducts in Humans |
[Bladder Cancer]
1997 |
$40,000 |
$690,180 |
| RANASINGHAGE C SAMARATUNGA, PHD
Radiodosimetry for the Treatment of Skeletal Lesions |
[Radiation]
1997 |
$19,806 |
|
| MICHELLE CRAIG BARTON, PHD
A cell-free model of p53 nuclear transport dysfuntion in breast cancer cells |
[Breast Cancer]
1997 |
$40,000 |
|
| ZALFA A ABDEL-MALEK, PHD
Elucidation of the Role of the MCI Receptor Gene as a Tumor Susceptibility Gene |
[Skin Cancer]
1997 |
$20,000 |
$1,236,364 |
| JOANNA GRODEN, PHD
A Human Helicase and its Effects on Cancer Predisposition and Genomic Instablility |
[Genetic Research]
1997 |
$40,000 |
$11,596,062 |
| SOHAIB A KHAN, PHD
Mechanism of Estrogen Action: Estrogen Receptor Associated Proteins |
[Breast Cancer]
1995 |
$40,000 |
$2,364,454 |
| ZALFA A ABDEL-MALEK, PHD
Protective Role of Melanin Against Photocarcinogenesis |
[Skin Cancer]
1993 |
$39,996 |
$1,633,312 |
|
TOTAL: |
$995,398 |
$46,477,060 |
|
Cincinnati Children’s Hospital Medical Center |
Funded |
Generated |
|
|---|---|---|---|
| SAULIUS SUMANAS, PHD
Inhibition of Etv2 function as a novel strateg to prevent tumor-induced |
[Tumor Studies] 2013 |
$60,000 |
$50,000 |
| GANG HUANG, PHD
Molecular mechanisms of leukemogenesis mediated by MLL-partial tandem duplication (MLL-PTD) |
[Leukemia] 2011 |
$60,000 |
$1,426,230 |
| RUHIKANTA MEETEI, PHD
Functional and Molecular Characterization of two new members of the Bloom |
[Genetic Research] 2010 |
$60,000 |
|
| TAKIKO DAIKOKU, PHD
Pten-Akt-Cox2 Signaling Axis in Endometrial Cancer |
[Endometrial Cancer] 2010 |
$60,000 |
$5,488,307 |
| ANIL G JEGGA, DVM
Functional Polymorphisms in p53 Response Elements |
[Gene Mutation] 2008 |
$50,000 |
|
| BRIAN ANDREW GEBELEIN, PHD
A New Tumor Suppression Pathway in Leukemia |
[Leukemia] 2008 |
$50,000 |
|
| VRUSHANK G DAVE, PHD
PTEN/PI3K/AKT Pathway in Lung Cancer |
[Lung Cancer] 2007 |
$50,000 |
$308,000 |
| JAMES MULLOY, PHD
Genetic screen for pathways cooperating with AMLl-ETO in leukemia induction |
[Leukemia] 2006 |
$50,000 |
$1,066,794 |
| YI GU, PHD
Role of Rac GTPases in p53-mediated Lymphomagenisis |
[Lymphoma] 2006 |
$25,000 |
|
| SUSANNE WELLS, PHD
DEK Oncogene Regulation by the Human Papillomavirus E6 Proteins |
[Cervical Cancer] 2003 |
$50,000 |
$2,864,905 |
| SUSAN WALTZ, PHD
Ron in Skin Cancer |
[Skin Cancer] 2001 |
$50,000 |
$1,658,546 |
| XINHUA LIN, PHD
Role of Dally-like, a Drosophila Glypican in Cell-Cell Signaling |
[Kidney Cancer] 2001 |
$50,000 |
$3,587,797 |
| RAPHAEL HIRSCH, MD
MHC – Ig Fusion Proteins for Induction pf Tumor Immunity |
[Molecular Genetics] 1997 |
$40,000 |
$1,757,955 |
| ROBERT ARCECI, MD, PHD
A Preclinical Model for Immunotherapy of AML |
[Leukemia] 1995 |
$40,000 |
$1,352,196 |
|
TOTAL: |
$695,000 |
$19,560,730 |